Telomere Maintenance Classification Shows Prognostic Value in Neuroblastoma

A study published in the Journal of Clinical Oncology evaluated whether telomere maintenance mechanism (TMM) classification could improve neuroblastoma risk assessment. Investigators examined 366 patients, including 259 classified as non–high-risk, divided into test (n = 116) and validation (n = 143) sets. Event-free survival (EFS) and overall survival (OS) were assessed using TMM classification, chromosomal copy-number alterations and gene expression profiles, with comparisons against standard prognostic factors.

Both TMM-based and gene expression-based classification distinguished non–high-risk patients with favorable and adverse survival outcomes in the test and validation sets. In multivariable analyses incorporating standard prognostic factors, TMM classification was the only risk factor retained in the final models: EFS hazard ratio 6.4 (95% CI, 3.9–10.6) and OS hazard ratio 29.4 (95% CI, 9.6–90.0), both P < .001. TMM classification also outperformed each alternative molecular classifier in pairwise models for both endpoints (P < .001 each).

The findings support further consideration of TMM-based risk stratification, particularly where avoiding overtreatment of biologically favorable disease is important. However, prognostic discrimination does not establish that TMM-guided treatment improves outcomes or safely reduces chemotherapy. Only the abstract was available; absolute survival estimates, follow-up duration and implementation details were not provided.